On July 26, 2023 Patrys reported its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 June 2023 (Press release, Patrys, JUL 26, 2023, View Source [SID1234633415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key highlights from this period include:

Investigation and audit suggest production issue for PAT-DX1 was a one-off event
Patrys commencing preparations for a replacement production run of PAT-DX1
No toxicology or safety issues identified in draft reports from GLP toxicology studies
US PTO grants two new patents for deoxymab technology providing coverage till 2039
The Company had a cash and short‑term investment balance of $4.0 million on 30 June 2023, with expected R&D rebate of $2.7 million.

Patrys CEO and MD, Dr James Campbell said:

"We are delighted that the investigation and audit by both the CDMO and our independent investigator have not identified any issue so far that is likely to impact on our future ability to manufacture GMP-grade PAT-DX1 for clinical trials…Based on the results to date, we believe we should be able to initiate a new production run in the coming months and have already commenced preparations for this."